{"id":916,"date":"2022-10-22T20:21:34","date_gmt":"2022-10-22T20:21:34","guid":{"rendered":"https:\/\/mebicar.pl\/sildenafil-citrate-how-does-it-support-brain-function\/"},"modified":"2026-08-13T18:24:26","modified_gmt":"2023-06-09T07:41:24","slug":"sildenafil-citrate-how-does-it-support-brain-function","status":"publish","type":"post","link":"https:\/\/mebicar.pl\/en\/sildenafil-citrate-how-does-it-support-brain-function\/","title":{"rendered":"Sildenafil citrate 171599-83-0: batch intake and storage protocol"},"content":{"rendered":"\n

Sildenafil citrate, CAS 171599-83-0, arrives in a laboratory as a fine crystalline solid catalogued with the molecular formula C28<\/sub>H38<\/sub>N6<\/sub>O11<\/sub>S and a molar mass of about 666.7 g\/mol. That formula covers the 1:1 citrate salt, not the free base, which is the single most common source of arithmetic error when working stock solutions are prepared. The sequence below sets out how a batch moves from the delivery bench to the qualified storage cabinet. See also our laboratory reagent: Pramiracetam czysto\u015b\u0107 substancji \u2265 99% 1000mg.<\/a>.<\/p>\n\n\n\n

Order of operations for an incoming batch<\/h2>\n\n\n\n
    \n
  1. Delivery intake.<\/strong> Record supplier, catalogue number, batch number, quantity and arrival date, and match every field against the accompanying certificate of analysis before the container leaves the receiving area.<\/li>\n
  2. Container inspection.<\/strong> Check seal integrity, desiccant condition where present, and the physical appearance of the solid. Caking, discolouration or a broken seal stops the batch at this step and sends it to a quarantine shelf.<\/li>\n
  3. Identity confirmation.<\/strong> Confirm identity against a reference standard by an orthogonal pair of techniques, typically infrared spectroscopy together with chromatographic retention matching. Supplier databases list a melting point near 190 °C for the salt, which serves as a coarse cross-check only.<\/li>\n
  4. Assay by liquid chromatography.<\/strong> The pharmacopoeial expectation for the material is not less than 98.0 percent and not more than 102.0 percent of sildenafil citrate, calculated on the anhydrous and solvent-free basis.<\/li>\n
  5. Organic impurity profiling.<\/strong> Run the chromatogram for three times the retention time of the main peak so that late-eluting species are captured rather than truncated.<\/li>\n
  6. Water and residual solvent determination.<\/strong> Karl Fischer titration and headspace chromatography supply the two correction terms without which the assay figure cannot be reported on the anhydrous, solvent-free basis.<\/li>\n
  7. Storage assignment.<\/strong> Move the accepted container to a dry, closed cabinet away from oxidising agents and direct light, with the opening date written on the label.<\/li>\n
  8. Dispensing.<\/strong> Weigh in a draught-free enclosure, close the primary container immediately, and never return an unused portion to the original packaging.<\/li>\n
  9. Record closure.<\/strong> File the certificate, the in-house chromatograms and the retention sample under the same batch number, so any later query resolves against archived data rather than memory.<\/li>\n<\/ol>\n\n\n\n

    Notes on the chromatographic step<\/h2>\n\n\n\n

    Two related substances dominate the impurity discussion for this material. Relative retention times reported for the pharmacopoeial system are about 1.0 for sildenafil, about 1.2 for sildenafil N-oxide and about 1.7 for the related compound designated A. System suitability requires resolution of not less than 2.5 between the N-oxide and the main peak, with a signal-to-noise ratio of not less than 10 for the impurity method. A run that fails either criterion produces numbers that look clean simply because the separation was inadequate.<\/p>\n\n\n\n

    The named process-related impurities trace back to the pyrazole carboxamide building blocks used in the synthesis: 1-methyl-4-nitro-3-propyl-1H-pyrazole-5-carboxamide and its reduced amino analogue. Their presence at low level is a synthesis fingerprint rather than a sign of decomposition, and the pattern is one reason a laboratory keeps its own chromatograms rather than relying on the supplier trace alone.<\/p>\n\n\n\n

    Why the salt form governs the calculation<\/h2>\n\n\n\n

    Because the catalogued material is a citrate salt, a mass of powder contains proportionally less of the parent molecule than the label figure might suggest at first glance. Any molar preparation must therefore start from the salt molar mass of roughly 666.7 g\/mol, and any conversion to free-base equivalent has to be stated explicitly in the notebook. Mixing the two conventions between analysts is the most frequent reconciliation problem seen in shared stock records.<\/p>\n\n\n\n

    Documentation that travels with the container<\/h2>\n\n\n\n

    The label carries the batch number, the opening date and the storage class. The folder carries the certificate of analysis, the identity spectra, the assay and impurity chromatograms, and the water content result. A retention sample drawn at first opening completes the set and makes it possible to distinguish a material problem from a method problem months later, which is the difference between a short investigation and an open-ended one. See also our laboratory reagent: Alfa GPC, czysto\u015b\u0107 \u2265 99% waga 1000mg netto.<\/a>.<\/p>\n\n\n\n

    Other catalogue items<\/h2>\n\n\n\n